Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of AstraZeneca (NYSE:AZN), a global branded pharmaceutical giant, tumbled as much as 13% after it rejected rival Pfizer's (NYSE:PFE) purported final offer to buy the company.

So what: Under the terms of the latest deal Pfizer was willing to pay $118.8 billion to purchase AstraZeneca (around $92.50 per share), whereas AstraZeneca's management team was looking for a considerably sweetened bid in the neighborhood of $98 or more per share. According to AstraZeneca's management team the deal would greatly undervalue the company current products and pipeline assets, and it doesn't believe that Pfizer's offer represents what's in the best interests of shareholders. In other words, the same speech shareholders have heard three times now. Pfizer now has until 5pm local time next Monday to make another offer under the U.K.'s takeover rules, otherwise it can't make another offer for AstraZeneca for six months.

Now what: With an offer that represented a 45% premium from whence the bidding began, I believe AstraZeneca's board has stubbornly thrown away what I consider to be a more-than-fair offer. The true value for Pfizer lies in purchasing AstraZeneca and moving its headquarters overseas to reduce it tax liability. That and combining its R&D and SG&A department would result in billions of savings – although it would take a couple of years to realize all those savings. AstraZeneca, though, has a lot of ongoing issues it needs to work through, but none more pressing than its ongoing patent issues. The deal would have made sense from a strategic standpoint, but I had trouble justifying the price following the first bid, let alone a third bid from Pfizer's standpoint. I would personally be surprised to see any competing bids come in, or for Pfizer to make a fourth bid for AstraZeneca. It's quite possible that, as I warned previously, shareholders could see nearly all of their buyout talk gains erode over the coming weeks.

The allure of big pharma is their hefty dividend payments. But this isn't the only space you can find high-yield income plays as our top analysts show below
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers